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Abstract 
INTRODUCTION: Amyloid imaging has been intergrated into diagnostic criteria for Alzheimer´s 
disease (AD). How amyloid tracers binding differ for different tracer structure and amyloid-β 
aggregate in autosomal dominant AD (ADAD) and sporadic AD is unclear.  
METHODS: Binding properties of different amyloid tracers were examined in(brain homogenates 
from six ADAD with APPswe, PS1M146V and PS1E∆9 mutations, thirteen sporadic AD and 
fourteen control cases.  
RESULTS: 3H-PIB, 3H-florbetaben, 3H-AZD2184 and BTA-1 shared a high- and a varying low-
affinity binding site in the frontal cortex of sporadic AD. AZD2184 detected another binding site 
(affinity 33 nM) in the frontal cortex of ADAD. The 3H-AZD2184 and 3H-PIB binding were 
significantly higher in the striatum of ADAD compared to sporadic AD and control. Polyphenol 
resveratrol showed strongest inhibition on 3H-AZD84 binding followed by 3H-florbetaben and 
minimal on 3H-PIB.  
DISCUSSION: This study implies amyloid tracers of different structures detect different sites on 
amyloid-β fibrils or conformations. 
 
Keywords: Alzheimer’s disease; amyloid-β; Autosomal dominant Alzheimer’s disease; Positron 
emission tomography; Resveratrol; Pittsburgh compound B; AZD2184; Florbetaben 
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1. Introduction 
The rapid development of molecular imaging enables measurement of brain amyloid-β (Aβ) plaques 
in vivo and facilitates an early detection of AD [1]. From the initial amyoid PET studies with 11C-
Pittsburgh compound B (PIB), three PET tracers 18F-florbetapir, 18F-florbetaben and 18F-
flutemetamol have been approved by US Food and Drug Administration and European Medical 
Assocation for use in clinical assessement of memory impairment to exclude AD.  
Subjects clinically diagnosed with AD without Aβ plaques at autopsy or PIB PET negative AD 
patients included in Aβ immunization trials [2] raise the questions of clinical variants of AD or 
misdiagnosis of AD. Appropriate use of biomarkers such as Aβ PET will improve diagnostic 
accuracy. Aβ tracers might vary in their binding properties to different Aβ fibrils and thereby 
provide new insight into pathophysiological mechanisms and variants of AD. In silico modelling 
studies have suggested six different surface and core binding sites on synthetic Aβ fibrils similarly 
using thioflavine-T compound (e.g. PIB), florbetaben and florbetapir [3-5]. Three binding sites have 
been demonstrated on synthetic Aβ fibrils [6]. A multiple-binding site model for Aβ tracers was 
suggested in AD autopsy brain where florbetapir, florbetaben and PIB mainly bind to a high-affinity 
site 1 (nanomolar range), BF-227 mainly with low-affinity to site 3 and FDDNP partly binding to 
site 2 [7].   
 
Autosomal dominant AD (ADAD) [8] characterized by atypical forms of Aβ aggregates represents 
interesting models to study target engagement of Aβ tracer to fibrillar as well as other Aβ 
conformations. Prominent 11C-PIB retentions have been reported in ADAD carrying PS1, APP 
mutation, in cortical and particularly subcortical brain regions [9-15]. In two exceptions APParc [13] 
and APPE∆693 [16], low cortical 11C-PIB retention was reported compared to sporadic AD (sAD) 
probably due to ring-shaped plaques or oligomeric Aβ accumulation in the brain. 
In the present study we compared the binding characteristic of Aβ PET tracers 3H-PIB, 3H-AZD2184, 
3H-florbetaben, and methyl-3H-BTA-1 in autopsy brain tissue from the frontal cortex and striatum of 
patients with sAD and ADAD respectively. An additional third binding site was detected by 
AZD2184 in the frontal cortex of ADAD patients as opposite to the other Aβ tracers. High AZD2184 
and PIB binding was measured in the striatum of ADAD compared to sAD. In addition, AZD2184 
competed in nanomolar range with anti-Aβ phenol compound resveratrol. The Aβ binding properties 
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seem to depend both on the chemical structures of Aβ tracers as well as the conformation of Aβ 
aggregates.  
 
2. Methods 
2.1 Materials:  
[3H]-2-[6-(methylamino)pyridin-3-yl]-1,3-benzothiazol-6-ol (3H-AZD2184, specific activity (SA) 
21.9 Ci/mmol) and AZD2184 were synthesized at the Karolinska Institutet PET Radiochemistry 
Laboratory, Stockholm, Sweden. [N-methyl-3H]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole 
(3H-PIB, SA 85 Ci/mmol) and Methyl-3H-BTA-1, (SA 84 Ci/mmol) were synthesized by Quotient 
Bioresearch, Cardiff, UK. [N-methyl-3H]4-[(E)-2-(4-{2-[2-(2-fluoroethoxy)ethyl]ethoxy}phenyl) 
ethenyl]-aniline (3H-florbetaben, SA 63 Ci/mmol) and florbetaben were synthesized by Bayer 
Healthcare Pharmaceuticals, Berlin, Germany. 2-(4´-Methylaminophenyl)benzothiazole (BTA-1), 
4,5-trihydroxy-trans-stilbene (resveratrol) were purchased from Sigma Aldrich, MO, USA. Fig. 6 
showed the chemical structures of amyloid tracers and resveratrol drawn using ChemDraw Standard 
14.0 (CambridgeSoft, Perkin Elmer, MA, U.S.A.).  
 
2.2 Sporadic AD, ADAD and control brain studies 
Frontal cortex and striatum (caudate nucleus and putamen) tissues from 13 patients with sAD (mean 
age 68.2 ± 8.5 y), clinically diagnosed and confirmed by pathological examination according to 
NINCDS-ADRDA criteria and 14 age-matched controls (mean age 74.1 ± 12.0 y) were obtained at 
autopsy and provided by the Netherlands Brain Bank, Netherlands Institute for Brain Research, 
Amsterdam, Netherland (Table 1). Brain tissue from six ADAD cases including three APPswe 
mutation carriers (mean age 63.3 ± 3.7 y), one PS1 M146V mutation carriers (age 48 y), were 
provided by the Brain Bank at Karolinska Institutet, Stockholm, Sweden. Brain tissue from one PS1 
M146V mutation carrier (age 43 y), and one PS1 E∆9 mutation carrier (age 66 y) were provided from 
the Department of Pathology, University of Helsinki, Helsinki, Finland. Permission to use autopsy 
brain material in experimental procedures was granted by the Regional Human Ethics committee in 
Stockholm and the Swedish Ministry of Health, and Ethics Committee of the Northern Ostrobothnia 
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Hospital District, Finland. Brain regions were dissected following recommendation of BrainNet 
Europe for fixation and anatomical dissection (www.brainnet-europe.org). 
(
2.3 Bielschowsky silver staining in ADAD and sporadic Alzheimer’s cases 
For neuropathological investigations, brain tissues from ADAD and sAD were fixed in buffered 4 % 
formaldehyde for 4-6 weeks, paraffinized and cut to 5 µm thick sections from the frontal medial 
gyrus and striatum. The sections were stained in the same laboratory condition by Bielschowsky 
silver impregnation according Yamamoto modification [17].  
 
2.4 Saturation assays in the frontal cortex homogenates from sporadic AD  
Post-mortem frontal cortex brain tissue homogenates (100 µg tissue) from patients with sAD were 
incubated with 0.01-250 nM 3H-AZD2184, 3H-PIB, 3H-florbetaben and methyl-3H-BTA-1 in 1 x 
PBS buffer (pH 7.4) for 2 hr at room temperature. Non-specific binding was determined in the 
presence of 1 µM BTA-1. Samples were run in triplicates and the specific binding was expressed in 
pmol/g tissue. The dissociation constant (Kd) and maximum number of binding sites (Bmax) was 
determined using non-linear regression models in GraphPad Prism version 6.0 (GraphPad Software, 
Inc., La Jolla, CA, USA). The saturation data were fit to one-site and two-site binding model, 
followed by F-test for model selection. Scatchard plots were obtained using GraphPad Prism to 
display the saturation data. 
 
2.5 Competitive binding studies in frontal cortical and striatum homogenates from sporadic AD and 
ADAD 
Competitive binding assays comparing different amyloid tracers in sAD frontal cortex brains were 
carried out by incubating homogenates (100 µg tissue) with 1.0 nM 3H-PIB, 2.5 nM 3H-florbetaben, 
1.5 nM 3H-AZD2184 or 2.0 nM methyl-3H-BTA-1 in the presence of unlabeled AZD2184, BTA-1, 
florbetaben and at concentrations ranging from 10-11-10-4 M. Competition binding assays comparing 
3H-PIB binding properties in sAD and ADAD (APPswe, PS1 M146V and PS1 E∆9) brain, were 
carried out by incubating frontal cortex and striatum homogenates (100 µg tissue) with 1.0 nM 3H-
PIB in the presence of BTA-1 and AZD2184 at concentrations ranging from 10-11-10-4 M. The 
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affinity constant (Ki) and percentage of displacement were determined by using non-linear 
regression one-site and two-site binding models derived from Cheng-Prusoff equation in GraphPad 
Prism, followed by F-test for model selection. The three-site binding of 3H-PIB/AZD2184 
competitive binding in the frontal cortex from ADAD were analyzed by additional fitting using two-
site binding model in GraphPad Prism with binding data at AZD2184 concentration ranging from 
10-9 to 10-4 M. 
 
2.6 Regional 3H-PIB and 3H-AZD2184 binding in brain tissue homogenates from sporadic AD, 
ADAD and healthy controls  
Single concentration binding studies using 1.0 nM 3H-PIB, and 1.5 nM 3H-AZD2184 were carried 
out by incubating homogenates (200 µg tissue) from the frontal cortex and striatum of sAD and 
ADAD (APPswe, PS1 M146V, PS1 E∆9 mutation carriers) and control brains. Non-specific binding 
was determined in the presence of 1 µM BTA-1.  
 
2.7 Interaction of resveratrol on amyloid tracer binding in the frontal cortical homogenates from 
patients with sporadic AD  
To determine the influence of phenols on amyloid tracer binding, frontal cortex homogenates from 
three sAD were incubated with 1.5 nM 3H-AZD2184, 2.5 nM 3H-florbetaben and 1.0 nM 3H-PIB in 
the presence of resveratrol at concentrations of 10-11-10-4 M. 
 
2.8 Statistical analysis 
Data were analyzed using GraphPad Prism version 6.0. Nonparametric Mann-Whitney test was used 
for comparisons between groups. All values are shown as means ± standard deviation (SD). Error 
bars in the figures represent standard error (S.E.M) values. Significant differences between groups 
were set at *p < 0.05, **p < 0.01, ***p < 0.001. 
 
3. Results 
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3.1 Bielschowsky silver staining in sporadic AD and ADAD 
When Bielschowsky silver staining was performed in brain sections of APPswe, PS1 M146V and 
PS1 E∆9 cases. ADAD showed a more intensive neuritic plaque staining in the layer I-III of frontal 
medial gyrus compared to sporadic AD cases (Fig. 1 A-D). The largest plaques were observed in the 
cortex of PS1 E∆9 case reaching the size of 100 µm in diameter. In PS1 M146V cases, neurofibrillry 
tangles and treads that were less present, with the feature of heavy loaded silver impregnated neuritic 
plaques indicating the presence of additional fibrillary pathology in the plaques. APPswe and PS1 
M146V cases showed intensive silver impregnation in the striatum; while for PS1 E∆9 cases as well 
as sporadic AD cases, there was an abundance of plaques in the striatum although the silver staining 
was weaker indicating their more diffuse nature (Fig. 1 E-H). 
 
3.2 Comparison of the binding properties of different amyloid tracers in the frontal cortex and 
striatum of sporadic AD and ADAD 
In order to characterize the binding sites of the amyloid tracers 3H-AZD2184, 3H-PIB, 3H-
florbetaben and methyl-3H-BTA-1, saturation-binding studies using increasing concentrations (0.01 - 
250 nM) of these tracers were performed in the frontal cortex homogenates from sAD patients. Fig. 2 
illustrates the saturation curves and Scatchard plots. Two binding sites could be obtained for 3H-
AZD2184 (Kd: 6.5 nM, 50.4 nM), 3H-PIB (Kd: 2.5 nM, 81.7 nM) and 3H-florbetaben (Kd: 9.7 nM, 
135 nM) respectively. Comparable binding affinity (Kd) for the high-and low-affinity binding sites, 
and Bmax for the high-affinity site were obtained for three amyloid tracers. No definite binding sites 
could be detected with the tracer methyl-3H-BTA-1 due to high percentage of non-specific binding. 
To further characterize and compare the binding properties of the amyloid tracer, competition studies 
were performed in the frontal cortex homogenates from sAD cases with 3H-AZD2184, 3H-PIB, 3H-
florbetaben and methyl-3H-BTA-1 in the presence of increasing concentration of unlabeled BTA-1, 
AZD2184 and florbetaben (10-11-10-4 M) respectively. Analysis of the competition results 
demonstrated the presence of a similar high-affinity site and varying low-affinity sites of 3H-
AZD2184, 3H-PIB and 3H-florbetaben in sAD frontal cortex (Fig. 3).  
3H-PIB showed two binding sites for unlabeled AZD2184 (Ki: 0.1 nM, 125 nM), BTA-1 (Ki: 0.9 nM, 
83 nM), and florbetaben (Ki: 0.1 nM, 190 nM) in the sAD frontal cortex. 3H-AZD2184 demonstrated 
a wide range of low-affinity binding sites with unlabeled AZD2184 (Ki: 0.1 nM, 7 nM), BTA-1 (Ki: 
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0.1 nM, 53 nM), and florbetaben (Ki: 0.2 nM, 325 nM). For 3H-florbetaben, two sites with 
comparable affinities were obtained with AZD2184 (Ki: 0.5 nM, 24 nM), BTA-1 (Ki: 0.1 nM, 45 nM) 
and florbetaben (Ki: 0.1 nM, 32 nM) respectively. Methyl-3H-BTA-1 binding contained high 
percentage of non-specific component and one binding site was estimated for florbetaben ( 20 nM), 
AZD2184 ( 200 nM) and BTA-1 ( 1000 nM) (Fig. 3).  
To investigate the difference between amyloid binding sites in ADAD and sAD brain, 3H-PIB 
competitive binding assays were performed using unlabeled AZD2184 or BTA-1 in the frontal cortex 
and striatum from six ADAD patients (including three APPswe, two PS1 M146V and one PS1 E∆9 
mutation carriers). In the frontal cortex from ADAD, three binding sites were demonstrated using 
AZD2184 (Ki: 0.5 nM, 33 nM, 327 nM), while two binding sites with unlabelled BTA-1 (Ki: 1.3 nM, 
80 nM) (Fig. 4 A). In the striatum of ADAD, two binding sites were detected using AZD2184 (Ki: 
0.6 nM, 95 nM) and BTA-1 (Ki: 0.8 nM, 37 nM). The 3H-PIB/BTA-1 binding affinity was somewhat 
higher in the striatum of ADAD cases compared to that of sAD (Ki: 4.8 nM, 105 nM) (Fig. 4B).   
 
3.3 Regional amyloid tracer binding in autosomal dominant and sporadic Alzheimer’s disease 
The binding of a single concentration of 3H-PIB (1.0 nM) and 3H-AZD2184 (1.5 nM) was measured 
in the homogenates from frontal cortex and striatum of six ADAD cases (including three APPswe, 
two PS1 M146V, one PS1 E∆9 mutation carriers), thirteen sAD cases, and fourteen controls 
respectively. Although the three ADAD mutations showed different properties of plaque pathology 
(Fig. 1 A-H) the ADAD cases were analysed together due to few cases from each mutation. A 
significant higher number of 3H-PIB and 3H-AZD2184 binding sites were observed in the frontal 
cortex of both ADAD and sAD cases compared to healthy controls (Table 2).  A significant higher 
3H-PIB as well as the 3H-AZD2184 binding was measured in the striatum of ADAD cases compared 
to control cases while no significant difference in binding was observed between sAD and controls 
(Table 2). Of the DAD cases both cases with APPswe and the PSM146V encoded mutations showed 
heavy plaque load in the striatum (Fig. 1 E-H). 
 
3.4 Interaction of resveratrol with amyloid tracers binding in the frontal cortex of sporadic 
Alzheimer’s disease  
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To investigate the possible interactive mechanisms between resveratrol and Aβ tracers binding sites 
in sAD brain, competitive binding assays were performed using resveratrol (10-11-10-4 M) and 3H-
AZD2184 (1.5 nM), 3H-PIB (1.0 nM), 3H-florbetaben (2.0 nM) respectively in homogenates 
prepared from the frontal cortex of three sAD cases. Analysis of the resveratrol competition binding 
studies demonstrated an interaction with a high-affinity binding site for 3H-AZD2184 (Ki 5 nM),  
while for 3H-florbetaben to a low affinity site (Ki 238 nM) and a very low affinity site for  3H-PIB 
(Ki 1900 nM) (Fig 5).  
 
4. Discussion 
Amyloid PET imaging has advanced our understanding of the early pre-symptomatic deposition of 
fibrillar Aβ in patients with ADAD and sAD [14, 18, 19]. There is a need to understand the 
interaction of Aβ ligands on the different binding sites on the Aβ fibril β-sheet and to clarify their 
biological role and possible technical confounders [20-22]. In this study, we examined the in vitro 
properties of Aβ tracers and studied how different chemical structures (Fig. 6) could influence the 
interaction of different Aβ conformation characteristics in ADAD and sAD cortical and striatal brain 
tissue, providing a link between binding and Aβ neuropathology. 
Clinical studies using different Aβ PET tracers have shown comparable results in detecting the 
presence of fibrillar Aβ plaques in brain from sAD and mild cognitive impairment using 11C-PIB 
[23], 18F-florbetaben [24], 18F-florbetapir, 18F-flutemetamol [25, 26], 18F-NAV4694 [27]. Head to 
head comparison of 11C-PIB and 18F-AZD4694 have shown strong correlation in binding [27] as well 
as between the three tracers 11C-PIB, 18F-florbetapir and 18F-flutemetamol [28]. In Aβ microPET in 
transgenic AD rat brain, excessive NAV4694 (an AZD2184 analog) blocked only 10-25 % 11C-PIB 
binding, suggesting that these two tracers may bind to different sites or forms of Aβ [29]. Such 
competitive experiment is highly informative, but not available in AD patients. 
3H-PIB binding correlates with amyloid plaques loads in sAD brain [30, 31], including neuritic 
plaques, cerebral angiopathy (CAA), diffuse plaques but not amorphous amyloid plaques in AD 
brain [32]. 18F-flutemetamol [26], 18F-florbetapir [33] and 18F-florbetaben PET has shown high 
sensitivity and specificity for the detection of histopathology-confirmed neuritic Aβ plaques. A 
subfraction of Aβ has been found containing high-affinity 3H-PIB site in sAD brain [34]. Recent 
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studies reported that Thal phase but not CERAD score correlate with PIB SUV from antemortem 
imaging , and suggesting that diffuse plaques may contribute to the PIB signal in PET imaging [32].  
From the chemical structure perspective, Thioflavine T derived tracer 3H-AZD2184, 3H-PIB, methyl-
3H-BTA-1 and stilbene derived tracer 3H-florbetaben all share a planar structure. In addition, 
florbetaben contains a more flexible polyethylene glycol (PEG) chain, which maintain lipophilicity 
and neutrality may influence the compounds engagement with β-sheet structure [35]. All studied Aβ 
tracers (3H-florbetaben, 3H-AZD2184, 3H-PIB) except 3H-Me-BTA-1, showed both a high- and low-
affinity binding sites in AD brain tissue, in agreement with earlier studies [7]. AZD2184 showed 
higher affinity of binding sites in the frontal cortex of sAD as well as a third binding site in the 
frontal cortex of ADAD, supporting multiple binding site model on fibrillar Aβ in brain. Earlier 
biophysical modeling studies have identified six possible binding sites for Aβ tracers PIB, BTA-1 
and Thioflavine T [3, 4]. Florbetaben, florbetapir and PIB that of different scaffolds share a common 
binding mode to surface groove, while the particular binding position and affinity might vary 
between different amyloid tracer and morphology of Aβ fibril [5] which is in line with  present study. 
When the binding profile of AZD2184 and thioflavine was studied by molecular docking and 
molecular dynamic simulation four binding sites were observed on the Aβ fibril where three with the 
fibril and one on the two sides of the Met35 residue on the surface [35]. The binding affinity of 
AZD2184 was found to be higher than thioflavine due to electrostatic interaction and spatial 
restriction [35]. Additionally, factors such as lipophilicity, pKa and the overall tracer structure may 
influence the tracer binding properties and the low non-specific binding of 3H-AZD2184 has been 
attributed partly to its low lipophilicity (3H-AZD2184 < 3H-PIB < 3H-florbetaben < Methyl-3H-BTA-
1) [36, 37]. 
 
We found that resveratrol interacted with the rank of order AZD2184 > florbetaben > PIB. Several 
possible mechanisms have been proposed regarding resveratrol-Aβ interaction, including specific 
conformation or non-covalent interaction with β-sheet structure [38] or with Aβ sequence such as the 
Aβ17-21 aromatic phenylalanine residue . Resveratrol are currently under clinical trial and phase II 
clinical trial in AD patients (NCT01504854). Interestingly enough resveratrol is phenol with stilbene 
structure. Resveratrol has been shown to inhibit synthetic Aβ aggregation and toxicity in vitro [39], 
and detected fluorescence of Aβ plaques similarly as Thioflavin T in post-mortem AD brain slides 
[40, 41]. The indication of direct binding of resveratrol to Aβ has raised an interest in developing 
resveratrol derivatives as potential Aβ PET tracers [42] and luminescent conjugated polymers as well 
as AD treatment agent. In a recent study administration of resveratrol (200 mg/day) for 26 weeks in 
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healthy, overweight older adult showed an improvement in memory performance as well as 
improved glucose metabolism [43]. 
 
Recent Alzheimer Disease Neuroimaging Initiative (ADNI) study and Dominantly Inherited 
Alzheimer Network (DIAN) has identified higher total Aβ load and less varitiety in comorbidity in 
ADAD brain [44]. We examined the properties of different Aβ tracers in brain tissue from mutation 
carriers with different characteristic AD pathology [45-49] and compared with that in sAD. We 
demonstrated that the number of striatal 3H-PIB and 3H-AZD2184 binding sites in ADAD was 
higher compared to sAD, and did not differ in the frontal cortex between two AD groups. This 
observation is in agreement with an earlier report [10], which also demonstrated a higher 11C-PIB 
retention in vivo in the striatum of PS1 E∆9 AD patients compared to sAD. The lower intensity of 
silver impregnation of the plaques (mainly diffuse) in the striatum of PS1 E∆9 mutation case 
underline the unique biochemical feature of the fibrillation of that mutation. PS1 E∆9 mutation 
carriers are known for their characteristic pathology of “cotton wool” plaques and CAA in the frontal 
cortex and widespread small diffuse Aβ plaques devoid of dystrophic neurites in the striatum [48]. 
The finding suggests that Aβ tracers can detect diffuse plaques. The arctic APP mutation carriers are 
lacking the β-sheet formation and show low 11C-PIB brain retention [13]. A very high plaque load is 
presented in the APPswe and PS1 M146V brain tissue. Despite that Aβ tracers have been suggested 
to bind to late fibrillar forms, the findings in the present study suggest that intensity of the binding 
thus not only depends on the morphological feature of the silver impregnation but probably rather 
more to specific biochemical properties of the plaques especially in the particular mutation the 
sensitivity of the ligand binding even to the mutation-specific earlier/diffuse plaque.  
 
There are some limitations of this study. Firstly, the fact that the availably of autopsy brain material 
is rare from these very unusual mutations which do not allowing large-scale studies. Secondly, in 
vitro solid-state nuclear magnetic resonance studies suggest that the molecular structures of Aβ 
fibrils vary in different sAD brains, which may contribute to the observed variation [50]. For quality 
control of the present study, the experiments were therefore repeated independently more than time 
and the binding curve analysis were evaluated independently and discussed between three of the 
authors. Thirdly, the variance in the competitive binding studies with resveratrol and different 
amyloid tracer were rather large as resveratrol is not specific for Aβ fibrils. 
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Understanding the binding mode of different amyloid tracers to brain Aß aggregates may facilitates 
the development of new early biomarkers as well as designing new drug targets for AD therapies. 
Future study regarding the pathological properties of the arctic and E293 ∆ mutations brains 
including studies of regional tau deposition and astrocytes activation will be insightful. New 
strategies for developing new Aß tracers that can detect smaller forms of Aß oligomeric forms as 
well protofibril are of great interest and should be tested in in silico modeling as well as in ADAD 
especially arctic mutation brain tissue and further also be explored by in vivo imaging in ADAD 
subjects at risk as well as sAD patients . Competitive binding using different amyloid compound in 
vivo in AD patients would be informative for but might be difficult due to the high concentrations 
needed of the tracers. In addition, it will be of clinical relevance to study how differences in 
properties of amyloid tracers could discriminate between rapidly progressive AD compared to slowly 
progressive AD cases and also might detect variants of late-onset sAD with divergent Aß pathology.  
(
To conclude, the studied Aβ tracers in the present study showed multiple binding sites and different 
binding properties in ADAD in comparison to sAD brains. AZD2184 detected, a third Aβ binding 
sites in the ADAD frontal cortex. High binding of the Aβ tracers in ADAD striatal tissue suggests 
conformal differences of amyloid aggregates in ADAD compared to sAD, confirming earlier in vivo 
PET observations in the cortex and striatum of sAD and ADAD patients. The anti-amyloid phenol 
compound resveratrol interacted in Nano molar range with AZD2184 but showed less affinity for 
florbetaben followed by PIB. Studies of the target similarity, differences as well as selectivity 
properties between the different amyloid tracers and in vivo-postmortem validation will facilitate the 
development of new imaging and therapeutic agents action on specific Aß conformational aggregates. 
(
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Table 1 
Demographic information for sporadic and autosomal dominant Alzheimer's disease cases 
Cohort N Age (range) 
Sex 
(F/M) 
APOE ε4 
(0/1/2) Disease duration (y) 
Postmortem 
delay (h) 
sAD 13 68.9 ± 8.5 
(58–81) 
7/6 3/3/7 6.1 ± 3.2 5.0 ± 0.9 
ADAD 6 57.8 ± 10.6 
(43–68) 
3/3 4/1/1 9.5 ± 4.0 19.6 ± 8.7 
APPswe 3 56–68 0/3 2/0/1 9.3 ± 2.2 21.7 ± 1.3 
PS1 
M146V 
2 43–48 2/0 1/1/0 4–10 28 
PS1 EΔ9 1 66 1/0 1/0/0 14 5 
Ctrl 14 74.1 ± 12.0 
(50–88) 
5/9 14/0/0 — 7.3 ± 3.8 
Abbreviations: sAD, sporadic Alzheimer's disease; ADAD, autosomal dominant Alzheimer's disease; 
APPswe, Swedish APP mutation carrier; PS1 M146V, Presenilin 1 M146V mutation carrier; PS1 
EΔ9, Presenilin 1 exon 9 deletion; Ctrl, healthy age-matched controls; APOE, apolipoprotein E; 0/1/2, number 
of ε4 allele. 
NOTE. Data are shown as mean ± standard deviation (SD). 
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Table 2 
Regional distribution of amyloid tracer 3H-PIB (1.0 nM) and 3H-AZD2184 (1.5 nM) binding in brain from 
sporadic, autosomal dominant Alzheimer's disease and healthy controls 
Brain 
region Ligand ADAD sAD Control 
Frontal 
cortex 
3H-PIB (pmol/g tissue) 212.2 ± 46.5** 
(n = 5) 
219.0 ± 66.6*** 
(n = 8) 
15.4 ± 20.5 
(n = 14) 
3H-AZD2184 (pmol/g 
tissue) 
409.9 ± 171.6** 
(n = 5) 
273.4 ± 103.7*** 
(n = 8) 
19.9 ± 31.0 
(n = 14) 
Striatum 3H-PIB (pmol/g tissue) 133.7 ± 43.5*** 
(n = 6) 
53.7 ± 68.9# (n = 7) 5.6 ± 8.3 (n = 8) 
3H-AZD2184 (pmol/g 
tissue) 
237.5 ± 85.2* 
(n = 6) 
179.7 ± 172.6 (n = 7) 27.7 ± 32.6 
(n = 6) 
Abbreviations: sAD, sporadic Alzheimer's disease; ADAD, autosomal dominant Alzheimer's disease; 3H-
PIB, 3H-Pittsburgh compound B. 
NOTE. Data are presented as means ± standard deviation (SD). 
NOTE. Significant differences compared to control group (Mann–Whitney U test) are indicated by *P < .05, 
**P < .01, ***P < .001. Significant difference between ADAD and sAD group is indicated by #P < .05. 
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